Clinical trial updates for malignant brain tumors

Clinical Neurology

Volumn 51, Issue 11, 2011, Pages 853-856

  Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain tumor; Gene therapy; Genomic therapy; Image guided neurosurgery; Robotics

Indexed keywords

BETA INTERFERON; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; SMALL INTERFERING RNA; TEMOZOLOMIDE;

ANAPLASTIC OLIGOASTROCYTOMA; ANAPLASTIC OLIGODENDROGLIOMA; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DOWN REGULATION; DRUG SAFETY; ENZYME MODIFICATION; GENE THERAPY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; JAPAN;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GLIOMA; HUMANS; ROBOTICS; SURGERY, COMPUTER-ASSISTED;

EID: 84856466318     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: 10.5692/clinicalneurol.51.853     Document Type: Conference Paper

References (10)

1. Natsume A, Wakabayashi T, Ishii D, et al. A combination of IFN-beta and temozolomide in human glioma xenograft models; implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 2008;61:635-639.
2. Aoki T, Matsutani M, Hashimoto N. Management of glioblastoma. Expert Opin Pharmacother 2007;8:1-14.
3. Wakabayashi T, Kayama T, Nishikawa E, et al. A multicenter phase I trial of interferon-beta and temozlomide combination therapy for high grade gliomas (INTEGRA study). Jpn J Clin Oncol 2008;38:715-718.
4. Wakabayashi T, Hatano N, Kajita Y, et al. Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol 2000;49:57-62.
5. Natsume A, Ishii D. Wakabayashi T, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 2005;65:7573-7579. (Pubitemid 41297227)
6. Kato T, Natsume A, Toda H, et al. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxicity of temozolomide in GBM-initiating cells. Gene Therapy 2010;17:1363-1371.
7. Yoshida J, Mizuno M, Fujii M, et al. Human gene therapy for malignant gliomas (Glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Human Gene Therapy 2004;15:77-86. (Pubitemid 38147190)
8. Wakabayashi T, Natsume A, Hashizume Y, et al. A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Medicine 2008;10:329-339. (Pubitemid 351517089)
9. Motomura K, Natsume A, Kishida Y, et al. Benefits of Interferon-β and Temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer 2011;117:1721-1730.
10. Wakabayashi T, Kayama T, Nishikawa R, et al. A multicenter phase I trial of combination therapy with interferon-beta and temozolomide for high-grade gliomas (INTEGRA study): the final report. J Neurooncol 2011, Feb. 14 (Epub ahead of print).